|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||
| Current assets: | ||||||||||||
| Cash | ||||||||||||
| Prepaid expenses | ||||||||||||
| Offering costs | ||||||||||||
| Other receivables | ||||||||||||
| Total current assets | ||||||||||||
| Investment held in Trust Account | ||||||||||||
| Total assets | ||||||||||||
| Liabilities and Shareholders’ Deficit: | ||||||||||||
| Current liabilities: | ||||||||||||
| Accounts payable and accrued expenses | ||||||||||||
| Due to related party | ||||||||||||
| Promissory notes – related party | ||||||||||||
| Due to HCYC | ||||||||||||
| Other liabilities current | ||||||||||||
| Related Party | ||||||||||||
| Total other liabilities current | ||||||||||||
| Total current liabilities | ||||||||||||
| Deferred underwriting commission | ||||||||||||
| Total liabilities | ||||||||||||
| Ordinary shares subject to possible redemption, 6,900,000 shares at redemption value of $10.29 per share as of March 31, 2023 | ||||||||||||
| Ordinary shares subject to possible redemption, 1,335,250 shares at redemption value of $12.00 and $11.41 per share as of September 30, 2025 and December 31, 2024 respectively | ||||||||||||
| Shareholders’ Deficit: | ||||||||||||
| Ordinary Shares, $0.0001 par value; 200,000,000 shares authorized; 2,134,200 shares issued and outstanding at September 30, 2025 and December 31, 2024 respectively | ||||||||||||
| Additional paid-in capital | ||||||||||||
| Accumulated deficit | ||||||||||||
| Total Shareholders’ Deficit | ||||||||||||
| Total Liabilities, Temporary Equity and Shareholders’ Deficit |
Loading...
